tradingkey.logo


tradingkey.logo


Fortrea Holdings Inc

FTRE
9.070USD
-0.480-5.03%
āļ›āļīāļ” 03/27, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
803.60MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Fortrea Holdings Inc āļšāļĢāļīāļĐāļąāļ—

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

āļ‚āđ‰āļ­āļĄāļđāļĨ Fortrea Holdings Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™FTRE
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Fortrea Holdings Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJun 16, 2023
āļ‹āļĩāļ­āļĩāđ‚āļ­Thakrala (Anshul)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™15500
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Jun 16
āļ—āļĩāđˆāļ­āļĒāļđāđˆ8 Moore Drive
āđ€āļĄāļ·āļ­āļ‡DURHAM
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ27709
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ18774950816
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.fortrea.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™FTRE
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJun 16, 2023
āļ‹āļĩāļ­āļĩāđ‚āļ­Thakrala (Anshul)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Fortrea Holdings Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Chairman of the Board
Chairman of the Board
98.13K
+63.69%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Lead Independent Director
Lead Independent Director
13.64K
+53.40%
Mr. Edward A. Pesicka
Mr. Edward A. Pesicka
Independent Director
Independent Director
13.64K
+53.40%
Mr. David Ross Smith
Mr. David Ross Smith
Independent Director
Independent Director
9.54K
+53.41%
Ms. Machelle Sanders
Ms. Machelle Sanders
Independent Director
Independent Director
7.28K
--
Ms. Jill Mcconnell
Ms. Jill Mcconnell
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mark Morais
Mr. Mark Morais
Chief Operating Officer and President - Clinical Services
Chief Operating Officer and President - Clinical Services
--
--
Ms. Hima B. Inguva
Ms. Hima B. Inguva
Investor Relations
Investor Relations
--
--
Ms. Erin L. Russell
Ms. Erin L. Russell
Independent Director
Independent Director
--
--
Mr. Anshul Thakrala
Mr. Anshul Thakrala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Chairman of the Board
Chairman of the Board
98.13K
+63.69%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Lead Independent Director
Lead Independent Director
13.64K
+53.40%
Mr. Edward A. Pesicka
Mr. Edward A. Pesicka
Independent Director
Independent Director
13.64K
+53.40%
Mr. David Ross Smith
Mr. David Ross Smith
Independent Director
Independent Director
9.54K
+53.41%
Ms. Machelle Sanders
Ms. Machelle Sanders
Independent Director
Independent Director
7.28K
--
Ms. Jill Mcconnell
Ms. Jill Mcconnell
Chief Financial Officer
Chief Financial Officer
--
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2021
FY2020
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
North America
332.70M
47.44%
Europe
213.20M
30.40%
Other
155.40M
22.16%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļĒāļąāļ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāđ€āļ›āļīāļ”āđ€āļœāļĒāļˆāļēāļāļ—āļēāļ‡āļšāļĢāļīāļĐāļąāļ—

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 28 āļĄāļĩ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 28 āļĄāļĩ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
14.12%
The Vanguard Group, Inc.
8.88%
Goldman Sachs & Company, Inc.
8.49%
Corvex Management LP
4.82%
State Street Investment Management (US)
4.40%
āļ­āļ·āđˆāļ™ āđ†
59.29%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
14.12%
The Vanguard Group, Inc.
8.88%
Goldman Sachs & Company, Inc.
8.49%
Corvex Management LP
4.82%
State Street Investment Management (US)
4.40%
āļ­āļ·āđˆāļ™ āđ†
59.29%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
46.45%
Hedge Fund
22.74%
Investment Advisor/Hedge Fund
18.80%
Research Firm
12.44%
Pension Fund
1.61%
Bank and Trust
1.57%
Individual Investor
0.56%
Family Office
0.35%
Holding Company
0.05%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 8 āļ˜.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
861
101.77M
121.97%
--
2025Q3
941
101.78M
123.79%
-128.81K
2025Q2
971
101.91M
125.96%
+8.10M
2025Q1
934
96.29M
123.92%
-15.90M
2024Q4
888
96.88M
127.14%
-3.71M
2024Q3
843
100.39M
126.92%
-3.95M
2024Q2
819
103.77M
114.37%
+7.39M
2024Q1
774
92.63M
104.75%
-1.02M
2023Q4
713
91.56M
111.23%
-6.24M
2023Q3
611
90.56M
44.21%
+51.30M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
BlackRock Institutional Trust Company, N.A.
12.67M
13.71%
-72.73K
-0.57%
Sep 30, 2025
The Vanguard Group, Inc.
8.03M
8.69%
-481.87K
-5.66%
Sep 30, 2025
Goldman Sachs & Company, Inc.
7.89M
8.54%
+148.09K
+1.91%
Sep 30, 2025
Corvex Management LP
4.51M
4.88%
--
--
Sep 30, 2025
State Street Investment Management (US)
4.07M
4.41%
-361.04K
-8.15%
Sep 30, 2025
Sessa Capital
3.99M
4.32%
--
--
Sep 30, 2025
Charles Schwab Investment Management, Inc.
2.65M
2.87%
+863.47K
+48.25%
Sep 30, 2025
AQR Capital Management, LLC
3.74M
4.04%
-2.78M
-42.66%
Sep 30, 2025
Fidelity Management & Research Company LLC
2.97M
3.21%
-11.70K
-0.39%
Sep 30, 2025
DWS Investments UK Limited
2.55M
2.76%
+921.34K
+56.67%
Sep 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Brandes US Small-Mid Cap Value ETF
1.39%
Invesco S&P Spin-Off ETF
0.97%
Invesco S&P SmallCap Health Care ETF
0.58%
Invesco S&P SmallCap 600 Revenue ETF
0.25%
Invesco S&P SmallCap 600 Pure Value ETF
0.23%
Schwab Fundamental U.S. Small Company ETF
0.17%
iShares S&P Small-Cap 600 Value ETF
0.16%
Humankind US Stock ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
State Street SPDR S&P 600 Small Cap Value ETF
0.13%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Brandes US Small-Mid Cap Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.39%
Invesco S&P Spin-Off ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.97%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.58%
Invesco S&P SmallCap 600 Revenue ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.25%
Invesco S&P SmallCap 600 Pure Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.23%
Schwab Fundamental U.S. Small Company ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.17%
iShares S&P Small-Cap 600 Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.16%
Humankind US Stock ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.14%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.14%
State Street SPDR S&P 600 Small Cap Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.13%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™